ETV4: A Potential Drug Target and Biomarker for Various Diseases
![Review Report on ETV4 Target / Biomarker](https://silexon.ai/img/target-biomarker-review.jpg?a=1)
![Content of Review Report on ETV4 Target / Biomarker](https://silexon.ai/img/target-biomarker-review-content.jpg?a=2)
ETV4: A Potential Drug Target and Biomarker for Various Diseases
ETV4 (E1AF), also known as E1-伪 interleukin-4 receptor, is a protein that is expressed in various tissues throughout the body. It is a member of the interleukin-4 receptor family, which is a protein that is involved in the regulation of immune and inflammatory responses.
ETV4 is a potential drug target, as it has been shown to play a role in the development and progression of various diseases. For example, studies have shown that high levels of ETV4 expression are associated with an increased risk of developing cardiovascular disease, and that blocking the activity of ETV4 may be a promising approach for treating this condition.
In addition to its potential as a drug target, ETV4 has also been shown to be a potential biomarker for various diseases. For example, studies have shown that ETV4 is expressed in the lungs, heart, and brain, and that it is involved in the regulation of immune responses and inflammation. This suggests that ETV4 may be a useful biomarker for diseases that affect these tissues, such as cancer, autoimmune disorders, and neurodegenerative diseases.
Overall, ETV4 is a protein that has the potential to be a drug target and a biomarker for various diseases. Further research is needed to fully understand its role and to develop safe and effective treatments.
Protein Name: ETS Variant Transcription Factor 4
Functions: Transcriptional activator (PubMed:19307308, PubMed:31552090). May play a role in keratinocyte differentiation (PubMed:31552090)
The "ETV4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ETV4 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
ETV5 | ETV6 | ETV7 | Eukaryotic translation initiation factor 2-alpha kinase | Eukaryotic translation initiation factor 2B | Eukaryotic translation initiation factor 3 (eIF-3) complex | Eukaryotic Translation Initiation Factor 4A (eIF-4A) | Eukaryotic Translation Initiation Factor 4E Binding Protein | EVA1A | EVA1A-AS | EVA1B | EVA1C | EVC | EVC2 | EVI2A | EVI2B | EVI5 | EVI5L | EVL | EVPL | EVPLL | EVX1 | EVX1-AS | EVX2 | EWSAT1 | EWSR1 | EXD1 | EXD2 | EXD3 | EXO1 | EXO5 | EXOC1 | EXOC1L | EXOC2 | EXOC3 | EXOC3-AS1 | EXOC3L1 | EXOC3L2 | EXOC3L4 | EXOC4 | EXOC5 | EXOC5P1 | EXOC6 | EXOC6B | EXOC7 | EXOC8 | Exocyst complex | EXOG | EXOGP1 | Exon junction complex | EXOSC1 | EXOSC10 | EXOSC10-AS1 | EXOSC2 | EXOSC3 | EXOSC4 | EXOSC5 | EXOSC6 | EXOSC7 | EXOSC8 | EXOSC9 | Exosome Complex | EXPH5 | EXT1 | EXT2 | EXTL1 | EXTL2 | EXTL2P1 | EXTL3 | EXTL3-AS1 | EYA1 | EYA2 | EYA3 | EYA4 | EYS | EZH1 | EZH2 | EZHIP | EZR | F10 | F11 | F11-AS1 | F11R | F12 | F13A1 | F13B | F2 | F2R | F2RL1 | F2RL2 | F2RL3 | F3 | F5 | F7 | F8 | F8A1 | F8A2 | F8A3 | F9 | FA2H